Table 3

Clinical profiles and sequenced hRasGRP4 cDNAs of the patients and healthy controls whose peripheral blood samples were obtained simultaneously as those in Figure 4A

Age

Sex

DAS28

Treatment

Clone 1

Clone 2

Clone 3

Clone 4

Clone 5

Healthy 1

32

F

0

none

FL

FL

Variant 5

FL

FL

Healthy 2

31

F

0

none

FL

FL

Variant 5

Variant 6

FL

Healthy 3

38

F

0

none

FL

FL

Variant 7

FL

FL

Healthy 4

38

F

0

none

FL

FL

FL

FL

RA 1

70

M

3.22

MTX 8 mg/week

+ IFX

FL

FL

FL

Variant 6

FL

RA 2

66

F

3.82

MTX 6 mg/week

FL

FL

FL

Variant 6

Variant 2

RA 3

61

F

2.17

MTX 10.5 mg/week

+ TAC 3 mg/day

Variant 5

Variant 5

Variant 5

Variant 5

Variant 5

RA 4

33

F

4.87

MTX 8 mg/week

+ PSL 5 mg/day

Variant 5

FL

Variant 5

FL

Variant 5

RA 5

78

M

2.65

MTX 6 mg/week

+ SSZ 1000 mg/day

FL

Variant6

Variant 5

Variant 5

Variant 6

RA 6

53

F

2.27

MTX 10 mg/week

+ PSL 2 mg/day

Variant 5

Variant 5

Variant 5

Variant 5

Variant 5

DAS28, The Disease Activity Score in 28 joints; FL, full-length; IFX, infliximab; MTX, methotrexate; PSL, prednisolone; RA, rheumatoid arthritis; SSZ, sulphasalazine; TAC, tacrolimus.

Hashimoto et al. Arthritis Research & Therapy 2011 13:R154   doi:10.1186/ar3470